Albuterol and pregnancy
Pro Research Analysisby 
Searched over 200M research papers
Albuterol and Pregnancy: A Comprehensive Overview
Short-term Effects of Inhaled Albuterol on Maternal and Fetal Circulations
Research has shown that the short-term use of inhaled albuterol, a common beta2-adrenergic agonist, does not significantly affect maternal or fetal circulations. A study involving 12 asthmatic patients between 33 and 39 weeks' gestation found that maternal blood pressures, heart rates, and fetal heart rates remained stable within the first two hours after dosing. Additionally, the systolic/diastolic ratios of the uterine arcuate and umbilical arteries, as well as fetal aortic velocities, were unaffected . This suggests that short-term use of albuterol is relatively safe for both mother and fetus during late pregnancy.
Agreement Between Maternal Report and Medical Records on Albuterol Use
A study examining the agreement between maternal self-reports and medical records for medication use during pregnancy found that albuterol was the most frequently reported asthma medication, with 77.9% of participants indicating its use. However, the agreement between maternal reports and medical records for albuterol use was moderate, with a kappa coefficient of 0.21 and 64.5% agreement. This indicates that maternal self-reports may capture more instances of albuterol use than medical records, highlighting the importance of considering both sources when studying medication impacts on perinatal outcomes .
Bronchodilator Responsiveness in Infants and Young Children
Research on bronchodilator responsiveness in infants and young children has shown that normal infants can exhibit bronchoconstriction, which can be reversed by inhaled beta-agonists like albuterol. A study involving 41 healthy infant volunteers demonstrated significant improvements in maximal expiratory flow rates after albuterol inhalation compared to placebo. Notably, the response was more pronounced in younger infants and those exposed to maternal smoking during pregnancy . This underscores the effectiveness of albuterol in managing airway responsiveness in infants, although maternal smoking may influence the degree of responsiveness.
Potential Harmful Effects of Beta2-Adrenergic Agonists During Pregnancy
The safety of beta2-adrenergic agonists, including albuterol, during pregnancy has been a topic of debate. These medications are often prescribed to treat asthma, pulmonary disease, and preterm labor. Concerns have been raised about a potential link between the use of these drugs and autism spectrum disorder in offspring. However, it is crucial to balance the potential risks with the known benefits of treating conditions like preterm labor, which is associated with significant morbidity and mortality. A critical appraisal of the literature suggests that while it is essential to investigate any potential harmful effects, the benefits of using beta2-adrenergic agonists in managing serious conditions during pregnancy should not be overlooked .
Conclusion
In summary, the use of albuterol during pregnancy appears to be relatively safe in the short term, with no significant adverse effects on maternal or fetal circulations. However, discrepancies between maternal reports and medical records highlight the need for comprehensive data collection methods in research. Additionally, while albuterol is effective in managing airway responsiveness in infants, the potential long-term effects and risks, such as the debated link to autism spectrum disorder, warrant further investigation. Balancing the benefits and risks of albuterol use during pregnancy remains crucial for optimal maternal and fetal health outcomes.
Sources and full results
Most relevant research papers on this topic